Investors Urged to Join Class Action Against Aquestive Therapeutics Over Allegations of Securities Fraud

Class Action Alert: Pomerantz Law Firm Takes on Aquestive Therapeutics

In an important development for investors in the healthcare sector, Pomerantz LLP has initiated a class action lawsuit against Aquestive Therapeutics, Inc. This lawsuit concerns allegations of securities fraud and other illicit business practices by the firm. As losses mount for shareholders, this class action aims to seek justice and compensation for those affected.

Background on the Lawsuit

The class action filed by Pomerantz is specifically directed at investors who incurred losses due to their purchases of Aquestive securities within a designated time frame, referred to as the Class Period. Those affected are encouraged to take action swiftly, with a deadline to apply as Lead Plaintiff approaching on May 4, 2026. Eligible investors are urged to reach out to Danielle Peyton at Pomerantz via the provided contacts.

When the class action was announced, it highlighted significant concerns emerging from the company's recent operations. On January 9, 2026, Aquestive received a letter from the U.S. Food and Drug Administration (FDA) pinpointing deficiencies related to its new drug application for Anaphylm (Dibutepinephrine) sublingual film. The FDA's findings noted that reviewing the application was still pending, resulting in the indefinite postponement of any label discussions.

Following the unfavorable news regarding Anaphylm, investors witnessed a drastic downturn in the company's stock price, plummeting by $2.30 per share—a staggering 37.04% drop—landing at $3.91 per share on the same day. Such a sharp decline has raised alarm bells about the company's transparency and adherence to regulations, leading to the current litigious situation.

Pomerantz: A Leader in Securities Class Action

Pomerantz LLP has a longstanding reputation for advocating on behalf of investors suffering from securities fraud. With over 85 years of experience, the firm has recovered millions in damages for victims of corporate misconduct. The firm was founded by the late Abraham L. Pomerantz, who is often referred to as the father of the modern class action. His legacy continues through the dedicated efforts of the firm's attorneys who are committed to holding corporations accountable.

For those interested in joining the class action lawsuit or acquiring additional information, relevant documentation, including details from the Complaint, can be accessed directly from the Pomerantz website. The firm's accessible online resources equip potential class members with pertinent information, empowering them to decide on participation in the lawsuit.

Moving Forward: Next Steps

Affected investors are advised to contact Pomerantz as soon as possible to secure their place in the lawsuit. When reaching out, investors should provide essential details such as their mailing address, phone number, and the number of shares purchased to facilitate the process. In these uncertain times, collective action is an essential tool for investors aiming to reclaim their losses.

As the case unfolds, stakeholders within the investment community are closely watching to gauge its implications on the future of Aquestive Therapeutics. The outcome of this class action may set a precedent for corporate accountability within the biotech sector, emphasizing the critical role regulatory bodies like the FDA play in safeguarding investor interests.

The Pomerantz Law Firm remains committed to its mission of defending the rights of investors against wrongdoing, and those involved in this class action can anticipate a vigorous legal fight to uphold their claims. Stay tuned for updates as this story develops, and do not hesitate to reach out if you believe you have been wronged by corporate practices.

For more information, visit Pomerantz Law Firm.